Subsidiaries
We've been pioneering discoveries for 150 years, and today our medicines help more than 71 million people across the globe.
Adverum Biotechnologies
Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness.
Akouos
Akouos is a precision genetic medicine company developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
Avid Radiopharmaceuticals, Inc
Avid's mission is to discover, develop, and deliver diagnostic solutions that improve global health by accelerating the development of new medicines.
Crossbridge Bio
CrossBridge Bio launched in 2023 with the aim of addressing a range of cancer indications via next-generation ADCs. The company originated from ADC tech developed at the University of Texas Health Science Center at Houston.
DICE Therapeutics
DICE is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration.
Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Orna Therapeutics
Orna Therapeutics is dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body.
Prevail Therapeutics, Inc
Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.
Protomer Technologies
Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body to automatically activate as needed, with variable dosing and targeted delivery.
Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.
SiteOne
SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders.
Versanis Bio
Versanis is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases.
Verve Therapeutics
Verve Therapeutics, Inc. is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines.